Where Will Novavax Be in 5 Years?
At the beginning of 2020, Novavax (NASDAQ: NVAX) had a valuation of $4 a share. Six months later, the company's stock sells for $47 a share. That's a dramatic shift in perception of value. What's the stock market seeing now that it didn't see in January?
In a word, COVID-19. More than 7 million people have caught the coronavirus, and more than 400,000 have died from it.
Novavax, like many biotech companies, is pursuing a COVID-19 vaccine. This involvement in the ongoing health scare has caused Wall Street to be far more optimistic about the company's future. Certainly, there's potential for Novavax to be far more valuable in 2025 than it is right now.
Source Fool.com